PD enters the back half of the week in a difficult spot: a fresh Morgan Stanley downgrade landed Tuesday, insiders have been selling consistently into the recent price recovery, and the stock has given back nearly 15% on the week to close at $9.39.
The analyst move is the sharpest signal. Morgan Stanley's Sanjit Singh downgraded PD to Underweight on July 21 — the first time the firm has moved to a negative rating — and cut the price target to $9.00 from $10.00, leaving it fractionally below Tuesday's close. That's a meaningful shift in tone from a bellwether firm, and it arrives just weeks after Truist raised its target to $11.00 on July 9, maintaining a Buy. The Street is now split: bulls at Truist and Canaccord point to a new CRO hire, AI-native customer momentum, and a $499 million ARR base as the foundation for a fiscal 2027 acceleration. Bears — now with Morgan Stanley as their most prominent voice — flag a deteriorating net revenue retention rate (down to 98%, the sixth consecutive quarterly decline) and TTM billings growth of just 4% year-over-year, well short of expectations. The consensus target has compressed to $9.43, barely above current levels, suggesting the Street as a whole sees little near-term upside.
The insider picture reinforces that cautious read. Executive Chairman Jennifer Tejada sold a combined 399,000 shares on July 16 and 17 — worth roughly $4.2 million — at prices between $10.41 and $10.70, well above where the stock closed Tuesday. The CFO and Chief Accounting Officer both sold smaller tranches on July 2 as well. Over the past 90 days, insiders have net-sold nearly $8.4 million worth of stock, with no offsetting purchases visible in the record. That's not a panic signal — many of these are likely programmatic dispositions — but the timing, selling into the stock's strongest month in a year, is worth noting.
Positioning in the lending market tells a different story — one that's notably calm given the week's drama. Borrow availability is extremely loose, running above 1,200%, meaning roughly twelve shares are available to lend for every one currently borrowed. Cost to borrow is negligible at under 0.5%, roughly flat on the week. Short interest, at 7.6% of the free float, has actually drifted lower from a month ago when it was running above 8.5%. In other words, the bears expressing a view through short positions have not piled in aggressively — and the lending market offers no squeeze dynamic to exploit. Options traders meanwhile have turned more call-leaning than usual. The put/call ratio at 0.41 is about 1.3 standard deviations below its 20-day average, closer to its 52-week low of 0.09 than its high of 0.85. That's a market leaning bullish through options even as the stock falls — possibly hedgers rolling or speculative buyers picking at the dip.
Peers provide useful context on the session's weakness. TEAM fell 6% on the day and WDAY dropped 4.1%, so some of PD's Tuesday move reflects sector-wide selling rather than stock-specific pressure. ASAN and CRM each fell 2–3%. Over the full week, PD's 14.6% decline stands out even against that soft backdrop — ZETA is the only peer down more on the week at nearly 6%.
The next earnings print is scheduled for September 3. Between now and then, the key friction point is whether the Morgan Stanley downgrade changes the buy-side conversation around net revenue retention, or whether the bulls' argument — that AI-native customer additions and the new CRO can inflect growth by fiscal 2027 — holds enough weight to stabilise the valuation near the $9 handle.
See the live data behind this article on ORTEX.
Open PD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
